Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C79H117N7O56S7.8Na |
Molecular Weight | 2469.161 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 27 / 27 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[H][C@]5(O[C@H]1[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]2[C@@H](COS([O-])(=O)=O)O[C@H](O[C@@]3([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]4([H])[C@@H](COS([O-])(=O)=O)O[C@H](OC)[C@H](OS([O-])(=O)=O)[C@H]4OC)O[C@H]3C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]2OS([O-])(=O)=O)O[C@@H]1C([O-])=O)O[C@H](COS([O-])(=O)=O)[C@@H](OCCOCCOCCOCCNC(=O)CCCNC(=O)C[C@H](NS(=O)(=O)C6=C(C)C(C)=C(OC)C=C6C)C(=O)N[C@H](CC7=CC=C(C=C7)C(N)=N)C(=O)N8CCCCC8)[C@H](OC)[C@H]5OC
InChI
InChIKey=DFRCPVPOZMLZGH-KIDSDGJESA-F
InChI=1S/C79H125N7O56S7.8Na/c1-39-33-46(115-4)40(2)41(3)69(39)143(95,96)85-44(71(89)84-45(72(90)86-24-14-13-15-25-86)34-42-18-20-43(21-19-42)70(80)81)35-51(88)82-22-16-17-50(87)83-23-26-124-27-28-125-29-30-126-31-32-127-52-47(36-128-144(97,98)99)132-76(64(120-9)55(52)116-5)136-59-57(118-7)66(122-11)78(139-62(59)73(91)92)135-54-49(38-130-146(103,104)105)133-79(68(142-149(112,113)114)61(54)140-147(106,107)108)137-60-58(119-8)65(121-10)77(138-63(60)74(93)94)134-53-48(37-129-145(100,101)102)131-75(123-12)67(56(53)117-6)141-148(109,110)111;;;;;;;;/h18-21,33,44-45,47-49,52-68,75-79,85H,13-17,22-32,34-38H2,1-12H3,(H3,80,81)(H,82,88)(H,83,87)(H,84,89)(H,91,92)(H,93,94)(H,97,98,99)(H,100,101,102)(H,103,104,105)(H,106,107,108)(H,109,110,111)(H,112,113,114);;;;;;;;/q;8*+1/p-8/t44-,45+,47+,48+,49+,52+,53+,54+,55-,56-,57-,58-,59-,60-,61-,62-,63+,64+,65+,66+,67+,68+,75-,76+,77+,78+,79+;;;;;;;;/m0......../s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C79H117N7O56S7 |
Molecular Weight | 2285.243 |
Charge | -8 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 27 / 27 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:02:16 GMT 2023
by
admin
on
Sat Dec 16 12:02:16 GMT 2023
|
Record UNII |
DUM42I2BVP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DUM42I2BVP
Created by
admin on Sat Dec 16 12:02:16 GMT 2023 , Edited by admin on Sat Dec 16 12:02:16 GMT 2023
|
PRIMARY | |||
|
11600660
Created by
admin on Sat Dec 16 12:02:16 GMT 2023 , Edited by admin on Sat Dec 16 12:02:16 GMT 2023
|
PRIMARY | |||
|
343776-67-0
Created by
admin on Sat Dec 16 12:02:16 GMT 2023 , Edited by admin on Sat Dec 16 12:02:16 GMT 2023
|
PRIMARY | |||
|
300000043979
Created by
admin on Sat Dec 16 12:02:16 GMT 2023 , Edited by admin on Sat Dec 16 12:02:16 GMT 2023
|
PRIMARY | |||
|
ORG-42675
Created by
admin on Sat Dec 16 12:02:16 GMT 2023 , Edited by admin on Sat Dec 16 12:02:16 GMT 2023
|
PRIMARY | Org 42675 [343776-67-0] |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
This compound (Org 42675) has a 10 times longer half-life compared with the original half-life of the direct thrombin inhibitor, while the thrombin inhibitory activity is maintained. An extra advantage of this product is the inhibitory activity on thrombin generation via antithrombin III (AT)-mediated factor (F)Xa inhibition. Finally, Org 42675 was far more active than the three reference compounds in an experimental thrombolysis model in rabbits.
|
||
|
ACTIVE MOIETY |
EP42675 was well tolerated in 100 healthy subjects enrolled in five phase I,
including single-dose and multiple ascending dose studies and a pharmacodynamic
interaction study with a combination of oral aspirin and clopidogrel. The only
drug-related adverse effects were minor episodes of bleedings (mostly at the
injection or blood sampling site) explained by the anticoagulant activity of
EP42675. Vital signs, physical examination, ECG (including the QTc interval) and safety laboratory parameters did not show any treatment-emergent clinically relevant abnormalities.
|